Ginkgo Bioworks

Ginkgo Bioworks is an American biotechnology company founded in 2008 by five scientists associated with the Massachusetts Institute of Technology. It describes its business as an “organism company”: rather than primarily selling a single branded therapeutic or consumer product, Ginkgo provides biological engineering capabilities to partner organizations. Its platform combines genetic design, laboratory automation, organism construction, screening, and data analysis to help customers develop microorganisms and other biological systems for industrial applications. The company’s commercial model is based largely on enabling other companies to develop and manufacture products with engineered biology. This approach is intended to reduce the cost and time required for customers to reproduce the early stages of synthetic-biology research internally. Potential application areas have included specialty chemicals, materials, food and agriculture, pharmaceuticals, and biosecurity. Ginkgo’s work has involved engineering microbes and developing the infrastructure needed to test large numbers of biological designs. Ginkgo became an early participant in the U.S. synthetic-biology venture ecosystem. In 2014, it became the first biotechnology company to join the Y Combinator accelerator. Its expansion was supported by substantial private funding, including a reported $45 million investment from Viking Global in 2015. By 2019, the privately held company was reported to have a valuation of approximately $4.2 billion and raised $290 million in September and a further $350 million in October of that year. The company expanded its physical and technical infrastructure in the Boston area. In 2020, it acquired property in Boston’s Raymond L. Flynn Marine Park for construction of a laboratory building and also occupied substantial space in the Innovation and Design Building. Ginkgo also acquired the primary assets of Novogy’s Microbial Engineering Platform in 2020, adding capabilities connected with microbial engineering. During the COVID-19 pandemic, Ginkgo entered the testing market, contributing to the company’s growth through biological testing and related infrastructure. Its business subsequently expanded through acquisitions and collaborations. These included FGen AG, which supplied an ultra-high-throughput screening platform; assets from Bitome, a real-time metabolite-monitoring company; Zymergen, acquired in an all-stock transaction announced in 2022; Bayer’s biologics research and development site in West Sacramento; and the assets of Altar and Circularis. The Bayer transaction also involved a new multi-year platform collaboration and the integration of research-and-development assets associated with Joyn Bio. Ginkgo became publicly traded on the New York Stock Exchange on September 17, 2021, following a merger with the special-purpose acquisition company Soaring Eagle. The transaction had originally been announced at a proposed valuation of $17.5 billion, although the company’s public-market status brought increased scrutiny of its revenue model and disclosures. The company has faced allegations concerning related-party transactions and the presentation of revenue connected with its SPAC combination, along with shareholder litigation and government inquiries reported in the early 2020s. Ginkgo’s brand positioning centers on synthetic biology as an industrial platform rather than on a conventional portfolio of consumer products. Its offerings are therefore best understood as engineering services, biological foundries, screening technologies, data systems, and collaboration programs. The company has also worked on biosecurity, including a reported collaboration with the Intelligence Advanced Research Projects Activity to develop ENDAR, a software tool intended to help identify genetic engineering in biological organisms. The company remains an active biotechnology platform business, although the specific scope of its current operations,…

Ginkgo Bioworks was established in 2008 by five MIT-affiliated scientists during the early development of commercial synthetic biology. The company adopted a platform-oriented model: instead of limiting itself to one therapeutic product or one engineered organism, it sought to provide the design, construction, testing, and analytical infrastructure that other companies could use to develop biological products. A significant early milestone came in 2014, when Ginkgo became the first biotechnology company accepted into Y Combinator. The accelerator connection helped place the company within the emerging technology-startup ecosystem, while later venture financing supported the expansion of its biological foundry operations. Ginkgo received $45 million from Viking Global in 2015. By 2019, it was described as one of the largest privately held biotechnology companies and was reported to have a valuation of $4.2 billion. It raised a further $290 million in September 2019 and $350 million in October of that year. The company developed facilities in Boston, including space in the Innovation and Design Building and other Cambridge locations associated with MIT spinouts. In 2020, Ginkgo purchased property valued at $25 million from Marcus Partners for construction of a 219,000-square-foot laboratory in the Raymond L. Flynn Marine Park. The company also acquired the primary assets of Novogy’s Microbial Engineering Platform in December 2020. These moves reflected an effort to build industrial-scale infrastructure for organism engineering rather than operate only as a conventional research consultancy. The COVID-19 pandemic broadened Ginkgo’s activities into testing and related public-health infrastructure. This expansion contributed to the company’s growth through 2021, alongside continued private financing and interest in synthetic biology. On May 11, 2021, Ginkgo announced a plan to become publicly traded through a merger with Soaring Eagle Acquisition Corp., a special-purpose acquisition company. The proposed transaction carried a stated valuation of $17.5 billion. Ginkgo announced that its New York Stock Exchange ticker would be DNA, a symbol previously associated with Genentech before that company was acquired by Roche. Trading began on September 17, 2021. The public listing exposed the company to intensified scrutiny. In October 2021, a market research firm alleged that Ginkgo’s reported revenue had been embellished through a complex structure involving related-party transactions. The allegations were followed by a reported U.S. Department of Justice inquiry. A shareholder lawsuit filed in November 2021 alleged that Ginkgo had misrepresented the sources of revenue in statements connected with its SPAC merger. Reporting at the time also noted that Ginkgo could not identify a single significant product manufactured and sold using its organisms, highlighting the difficulty of evaluating a platform company whose commercial output is often delivered through partnerships rather than a conventional product catalog. Ginkgo pursued an acquisition-led expansion in 2022. It announced an agreement to acquire FGen AG and its high-throughput screening platform, acquired assets from Bitome for real-time metabolite monitoring, and agreed to buy Zymergen in a transaction valued at approximately $300 million and structured as an all-stock deal. It also announced the acquisition of Bayer’s biologics research and development site in West Sacramento. That arrangement included a multi-year platform collaboration with Bayer and the integration of research-and-development assets associated with Joyn Bio, a joint venture connected to Bayer’s Leaps investment organization and Ginkgo. Later in 2022, Ginkgo announced transactions involving Altar, a France-based developer of adaptive laboratory evolution instruments, and Circularis, a California biotechnology company. These deals were intended to strengthen capabilities relevant to cell and gene therapy and to broaden the company’s biological engineering toolkit. Ginkgo was also reported to be working with the Intelligence Advanced Research Projects Activity on ENDAR, a software system intended to identify genetic engineering in organisms and provide an early warning of engineered biological threats. In March 2023, a former attorney general of Louisiana was reported to have launched an investigation into Ginkgo’s officers and directors. Together with the earlier revenue allegations, DOJ inquiry, and shareholder litigation, this episode formed part of the public controversy surrounding the company’s financial disclosures and governance. Ginkgo’s central business proposition nevertheless remained the development of an industrial synthetic-biology platform: a combination of biological design, automated experimentation, screening, data, and partnerships intended to help customers create organisms for commercial and public-sector applications. Current management, exact headquarters, present product status, and subsequent legal outcomes are not established by the supplied reference material and require updated verification.

1. 2022Acquisition-led platform expansion

   Ginkgo announces or completes transactions involving FGen, Bitome, Zymergen, Bayer’s biologics site, Altar, and Circularis.

   Source
2. 2021SPAC merger announced

   Ginkgo announces its plan to merge with Soaring Eagle at a proposed valuation of $17.5 billion.

   Source
3. 2021Public trading begins under DNA

   Ginkgo begins trading on the New York Stock Exchange on September 17 under the ticker DNA.

   Source
4. 2020Expansion of laboratory infrastructure

   Ginkgo acquires Boston-area property for a planned laboratory building and expands its physical presence in the Innovation and Design Building.

   Source
5. 2020Novogy platform assets acquired

   Ginkgo acquires the primary assets of Novogy’s Microbial Engineering Platform.

   Source
6. 2019Major private financing and valuation

   Ginkgo is reported to reach a $4.2 billion private valuation and raises $290 million in September and $350 million in October.

   Source
7. 2014First biotechnology company in Y Combinator

   Ginkgo becomes the first biotechnology company to join the Y Combinator accelerator.

   Source
8. 2008Ginkgo Bioworks is founded

   Five MIT-affiliated scientists establish Ginkgo Bioworks as a synthetic-biology company.

   Source

An industrial synthetic-biology platform and biological engineering partner that helps organizations design, build, test, and scale engineered organisms.

• Organism engineering platformSynthetic biology platform

  Ginkgo’s core offering combines genetic design, organism construction, automated laboratory work, screening, and biological data analysis. The platform is used with commercial and research partners seeking to engineer microorganisms or other biological systems for industrial purposes. It is a service and infrastructure model rather than a single mass-market product.

• Microbial engineeringIndustrial biotechnology

  Ginkgo develops engineered microbes for partner applications. Its work is intended to help customers produce biological compounds, materials, chemicals, or other outputs while avoiding the need to build the entire early-stage organism-design process internally.

• High-throughput screeningBiotechnology instrumentation and services

  Through internal development and acquisitions including FGen, Ginkgo has expanded its ability to screen large numbers of biological variants. High-throughput screening helps identify organisms or genetic designs with useful characteristics and is a central component of the company’s biological foundry model.

• Biological testing infrastructurePublic-health biotechnology2020

  During the COVID-19 pandemic, Ginkgo entered the testing market and developed related public-health capabilities. The supplied material does not establish a single current branded testing product or its present availability.

• ENDARBiosecurity software2022

  ENDAR, short for Engineered Nucleotide Detection and Ranking, was reported as a software tool developed with the Intelligence Advanced Research Projects Activity to help detect whether biological organisms have been genetically engineered. It was intended for early warning of bioweapons and other engineered biological threats.

• 2022Biosecurity detection collaboration

  United States

  Ginkgo worked with IARPA on ENDAR, a tool intended to identify signs of genetic engineering in biological organisms.

  Outcome. The reported objective was to provide earlier warning of engineered biological threats; the supplied material does not document deployment or commercial results.

  Source
• 2020COVID-19 testing expansion

  United States

  Ginkgo expanded into COVID-19 testing and related public-health infrastructure during the pandemic, contributing to the company’s growth through 2021.

  Outcome. The supplied sources describe testing as a growth driver but do not establish the full scope, duration, or current status of the program.

  Source

• 2022Acquire ZymergenM&A

  Ginkgo sought to broaden its synthetic-biology capabilities through the combination with another engineered-biology company.

  What changed. Ginkgo agreed to acquire Zymergen in an all-stock transaction.

  Aftermath. The announced transaction was valued at approximately $300 million; the supplied material does not provide further integration or operating outcomes.

  Announced transaction value. $300 million (2022 announcement)

  Source
• 2022Expand through Bayer biologics assets and collaborationM&A

  Ginkgo aimed to increase its research infrastructure and biologics capabilities while deepening its relationship with Bayer.

  What changed. Ginkgo announced plans to acquire Bayer’s West Sacramento biologics research and development site and enter a multi-year platform collaboration.

  Aftermath. The arrangement included integration of research-and-development assets associated with Joyn Bio.

  Source
• 2021Pursue public listing through Soaring Eagle mergerM&A

  Ginkgo sought to finance continued expansion of its synthetic-biology platform and move from private-company funding to public markets.

  What changed. The company announced a merger with SPAC Soaring Eagle at a proposed valuation of $17.5 billion and later began NYSE trading under DNA.

  Aftermath. The listing provided public-market access but was followed by scrutiny of revenue disclosures, related-party transactions, and the company’s SPAC-related statements.

  Proposed transaction valuation. $17.5 billion proposed valuation (2021 announcement)

  Source

• 2023Investigation into officers and directorsControversy

  A former attorney general of Louisiana was reported to have launched an investigation into Ginkgo’s officers and directors. The supplied material does not establish the investigation’s final outcome.

  Source
• 2021Revenue and related-party transaction allegationsControversy

  A market research firm alleged that Ginkgo embellished revenue through a complex structure involving related-party transactions. The allegations prompted reported scrutiny by the U.S. Department of Justice and a shareholder lawsuit alleging misleading statements related to the SPAC merger.

  Source

• 2022Ginkgo agrees to acquire FGen

  Ginkgo announced an agreement to acquire FGen AG and its proprietary ultra-high-throughput screening platform.

  M&A
  Source
• 2022Ginkgo acquires Bitome assets

  Ginkgo acquired assets from Bitome, a company focused on real-time metabolite monitoring.

  M&A
  Source
• 2022Ginkgo agrees to acquire Zymergen

  Ginkgo agreed to acquire Zymergen in an all-stock transaction valued at approximately $300 million when announced.

  M&A
  Source
• 2022Ginkgo expands through Bayer biologics site transaction

  Ginkgo announced plans to acquire Bayer’s biologics research and development site in West Sacramento and enter a multi-year platform collaboration with Bayer.

  M&A
  Source
• 2022Ginkgo acquires Altar and Circularis assets

  Ginkgo announced acquisitions involving Altar, an adaptive-laboratory-evolution instrument developer, and Circularis, strengthening capabilities relevant to cell and gene therapy.

  M&A
  Source
• 2022Ginkgo works with IARPA on engineered-organism detection

  Ginkgo was reported to be collaborating with the Intelligence Advanced Research Projects Activity on ENDAR, a tool designed to detect signs that biological organisms have been genetically engineered.

  OtherRegulation
  Source
• 2021Ginkgo announces public listing through Soaring Eagle merger

  Ginkgo announced plans to merge with SPAC Soaring Eagle at a proposed valuation of $17.5 billion.

  M&A
  Source
• 2021Ginkgo begins trading on the New York Stock Exchange

  Following its SPAC transaction, Ginkgo began public trading on September 17, 2021, under the ticker DNA.

  Other
  Source
• 2020Ginkgo acquires primary assets of Novogy’s Microbial Engineering Platform

  Ginkgo agreed to acquire the principal assets of Novogy’s microbial-engineering platform, expanding its organism-design capabilities.

  M&A
  Source
• 2014Ginkgo Bioworks joins Y Combinator

  Ginkgo became the first biotechnology company to participate in the Y Combinator startup accelerator.

  Other
  Source

1. Ginkgo Bioworks — Wikipedia